PMID- 29417945
OWN - NLM
STAT- MEDLINE
DCOM- 20190411
LR  - 20190802
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 39
IP  - 8
DP  - 2018 Aug
TI  - Emodin alleviates alternatively activated macrophage and asthmatic airway 
      inflammation in a murine asthma model.
PG  - 1317-1325
LID - 10.1038/aps.2017.147 [doi]
AB  - Alternatively activated macrophages (AAMs) are not only associated with asthma 
      but also lead to asthmatic airway inflammation and remodeling. Inhibition of AAMs 
      is an alternative therapeutic strategy for treating asthma. In this study we 
      investigated whether emodin (1,3,8-trihydroxy-6-methylanthraquinone), isolated 
      from the rhizome of Rheum palmatum, alleviated asthmatic airway inflammation and 
      reduced AAM polarization in a murine asthma model. Mice were sensitized with a 
      triple allergen mix containing dust mite, ragweed and aspergillus (DRA). In mice 
      with DRA-induced asthma, asthmatic inflammation was significantly enhanced. 
      Intraperitoneal injection of emodin (20 mg.kg(-1).d(-1), ip) 1 h prior to DRA 
      challenge on days 12-14 significantly decreased pulmonary eosinophil and 
      lymphocyte infiltration, mucus secretion and serum IgE production, as well as 
      IL-4 and IL-5 production in bronchoalveolar lavage fluid. In response to emodin 
      treatment, activated markers of AAM Ym-1, Fizz-1 and arginase-1 in the lung 
      tissues were remarkably decreased. In mouse bone marrow-derived macrophages 
      (BMDMs) in vitro, emodin (2-50 mumol/L) dose-dependently inhibited IL-4-induced 
      AAM polarization and STAT6 phosphorylation. Collectively, our results suggest 
      that emodin effectively ameliorates asthmatic airway inflammation and AAM 
      polarization, and it may therefore become a potential agent for the treatment of 
      asthma.
FAU - Song, Yun-Duan
AU  - Song YD
AD  - Department of Clinical Laboratory, Shanghai Pudong Hospital, Fudan University, 
      Shanghai, 201399, China.
FAU - Li, Xiao-Zong
AU  - Li XZ
AD  - Department of Clinical Laboratory, Shanghai Pudong Hospital, Fudan University, 
      Shanghai, 201399, China.
FAU - Wu, Ya-Xian
AU  - Wu YX
AD  - Engineering Research Center of Cell & Therapeutic Antibody, Ministry of 
      Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, 
      China.
FAU - Shen, Yao
AU  - Shen Y
AD  - Department of Respiratory Medicine, Shanghai Pudong Hospital, Fudan University, 
      Shanghai, 201399, China.
FAU - Liu, Fang-Fang
AU  - Liu FF
AD  - Department of Clinical Laboratory, Shanghai Pudong Hospital, Fudan University, 
      Shanghai, 201399, China.
FAU - Gao, Pei-Pei
AU  - Gao PP
AD  - Department of Pharmaceutical Preparation Section, Shanghai Pudong Hospital, Fudan 
      University, Shanghai, 201399, China.
FAU - Sun, Lei
AU  - Sun L
AD  - Engineering Research Center of Cell & Therapeutic Antibody, Ministry of 
      Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, 
      China. sunlei_vicky@sjtu.edu.cn.
FAU - Qian, Feng
AU  - Qian F
AD  - Engineering Research Center of Cell & Therapeutic Antibody, Ministry of 
      Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, 
      China. fengqian@sjtu.edu.cn.
AD  - Research Center for Cancer Precision Medicine, Bengbu Medical College, Bengbu, 
      233003, China. fengqian@sjtu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20180208
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Interleukin-5)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - KA46RNI6HN (Emodin)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Asthma/*drug therapy/pathology
MH  - Bronchoalveolar Lavage Fluid/cytology
MH  - Emodin/*therapeutic use
MH  - Immunoglobulin E/metabolism
MH  - Inflammation/*drug therapy/pathology
MH  - Interleukin-4/metabolism
MH  - Interleukin-5/metabolism
MH  - Lung/pathology
MH  - Macrophage Activation/*drug effects
MH  - Macrophages/metabolism
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Pulmonary Eosinophilia/drug therapy/pathology
PMC - PMC6289379
OTO - NOTNLM
OT  - IL-4
OT  - STAT6
OT  - airway inflammation
OT  - alternatively activated macrophage
OT  - asthma
OT  - emodin
EDAT- 2018/02/09 06:00
MHDA- 2019/04/12 06:00
PMCR- 2019/08/01
CRDT- 2018/02/09 06:00
PHST- 2017/07/13 00:00 [received]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2019/04/12 06:00 [medline]
PHST- 2018/02/09 06:00 [entrez]
PHST- 2019/08/01 00:00 [pmc-release]
AID - 10.1038/aps.2017.147 [pii]
AID - 115 [pii]
AID - 10.1038/aps.2017.147 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2018 Aug;39(8):1317-1325. doi: 10.1038/aps.2017.147. Epub 
      2018 Feb 8.